Who are MRI contrast-enhancing agents's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Elucirem (Gadopiclenol), MRI contrast-enhancing preparations.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mri-contrast-enhancing-agents.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MRI contrast-enhancing agents — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI contrast-enhancing agents (MRI contrast-enhancing agents) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MRI contrast agent. Area: Diagnostic Imaging.

phase 3 MRI contrast agent Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

MRI contrast-enhancing agents (MRI contrast-enhancing agents) — Medical University of Vienna. MRI contrast-enhancing agents improve visualization of anatomical structures and pathology by altering the magnetic properties of nearby water molecules during magnetic resonance imaging.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MRI contrast-enhancing agents TARGET	MRI contrast-enhancing agents	Medical University of Vienna	phase 3	MRI contrast agent
Elucirem (Gadopiclenol)	Elucirem (Gadopiclenol)	Johns Hopkins University	marketed	Gadolinium-based MRI contrast agent	Water protons (T1 relaxation enhancement)
MRI contrast-enhancing preparations	MRI contrast-enhancing preparations	Sanofi	phase 3	MRI contrast agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MRI contrast agent class)

Medical University of Vienna · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MRI contrast-enhancing agents — Competitive Intelligence Brief. https://druglandscape.com/ci/mri-contrast-enhancing-agents. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing